Gilead Sciences, INC Schedule 13D activist filings

Gilead Sciences has increased its beneficial ownership in Assembly Biosciences to 25.1% following a recent public offering.

Gilead Sciences has finalized its acquisition of Arcellx, Inc. following a successful tender offer and subsequent merger, making Arcellx a wholly owned subsidiary.

Gilead Sciences, Inc. announces a definitive agreement to acquire Arcellx, Inc. for approximately $8.1 billion, including a contingent value right, following a tender offer.

Gilead Sciences, Inc. has filed an Amendment No. 6 to Schedule 13D, updating its beneficial ownership in Arcus Biosciences, Inc. to 25.6% of outstanding common stock.

Gilead Sciences, Inc. increased its beneficial ownership in Assembly Biosciences, Inc. to 29% through a $45 million purchase of common stock and warrants.

Gilead Sciences, Inc.'s option to acquire additional shares in Arcus Biosciences, Inc., potentially increasing its stake to 35%, expired on July 13, 2025, leaving its beneficial ownership at 29.7%.

Gilead Sciences, Inc. has increased its beneficial ownership in Arcus Biosciences, Inc. to 35% through a series of stock purchases, including a recent public offering, reinforcing their strategic collaboration.

Gilead Sciences, Inc. has significantly increased its beneficial ownership in Arcus Biosciences, Inc. to 35% through a series of strategic share purchases and option exercises, reinforcing their ongoing collaboration.

Galapagos NV and Gilead Sciences, Inc. have entered into a Separation Agreement to demerge certain assets and cash into a new entity, SpinCo, while Galapagos NV sharpens its focus on innovative cell therapies for cancer.